Five quick questions and answers you should know before taking Orlistat 1.How does orlistat help with weight loss? Orlistat (the active ingredient in Alli) promotes weight loss by decreasing the amount of dietary fat absorbed in your intestines. Lipase, an enzyme found in the digestive tract, helps break down dietary fat into smaller components, so it can be used or stored for energy. Orlistat inhibits the work of lipase.
2.Does orlistat reduce belly fat? Orlistat is a medicine which can help you to lose weight if you are overweight or obese. Orlistat works by blocking chemicals (enzymes) in your gut which digest fat. Nearly a third of the fat that you eat is blocked by orlistat.
3.Does orlistat work if you don't eat fat? Orlistat will not stop you absorbing any of the calories from protein, carbohydrates or alcohol. You must continue to eat a healthy, low fat diet and take regular exercise to help you lose weight. You must achieve at least 5% weight loss within 3 months otherwise treatment with Orlistat may be stopped.
4.What happens if you take orlistat without eating? If there is no fat in one of your meals, or if you miss a meal, there is no need for you to take a dose of orlistat. Common side-effects include wind, loose stools and back passage (rectal) spotting, particularly at the beginning of treatment. These effects can be reduced by eating less fat in your meals.
5.Does Alli make you poop a lot? The main treatment effect occurs when an individual eats a meal with too much fat while taking alli (orlistat 60 mg) . Treatment effects may include: Loose or more frequent stools that may be hard to control. An urgent need to go to the bathroom.
Reference 1. "POISONS STANDARD JUNE 2017". Federal Register of Legislation. Therapeutic Goods Administration. June 2017. Retrieved 18 August 2017. 2.Schmid,
Randolph
E
(9
February
2007).
"FDA
OKs
First
Nonprescription Diet Pill". USA Today. Retrieved 9 June 2009. 3."Orlistat 120mg capsule blister pack". TGA. 11 April 2000. Retrieved 18 April 2018. 4. Siebenhofer, A; Jeitler, K; Horvath, K; Berghold, A; Posch, N; Meschik, J;
Semlitsch, T (2 March 2016). "Long-term effects of weight-reducing drugs in people with hypertension". The Cochrane Database of Systematic
Reviews.
3:
doi:10.1002/14651858.CD007654.pub4. PMID 26934640.
https://www.cmoapi.com/ https://www.cmoapi.com/product/orlistat/ https://www.facebook.com/Cmoapi-114510347044359/ https://www.pinterest.com/cmoapibiotech/boards/
CD007654.